Quarterly report · Q2
2269.TEDINET S100S7SR
Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥546.0bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥1.06T | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥517.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥44.4bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥43.2bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥43.4bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥74.2bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥43.9bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥48.1bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥48.3bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥27.9bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥69.4bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥33.4bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥30.4bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥34.9bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥1.21T | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥1.14T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.18T | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥421.1bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥384.9bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥786.7bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥751.3bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥757.0bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥82.1bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥63.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥78.4bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥60.9bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥88.7bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥64.9bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥25.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥85.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥25.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥15.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥36.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥26.0bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥4.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥54.7bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥20.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥100.13 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥58.54 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥247.39 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥118.52 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥61.65 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 61.7% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.7% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.6% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥303m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥303m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥1.1bn |
| jpcrp040300-q2r_E21902-000Foodreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥445.5bn |
| jpcrp040300-q2r_E21902-000Foodreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥445.2bn |
| jpcrp040300-q2r_E21902-000Foodreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥293m |
| jpcrp040300-q2r_E21902-000Foodreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥29.7bn |
| jpcrp040300-q2r_E21902-000Pharmaceutica002reportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥100.9bn |
| jpcrp040300-q2r_E21902-000Pharmaceutica002reportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥100.8bn |
| jpcrp040300-q2r_E21902-000Pharmaceutica002reportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥9m |
| jpcrp040300-q2r_E21902-000Pharmaceutica002reportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥15.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥546.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥546.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥303m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥45.6bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥292m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥292m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥786m |
| jpcrp040300-q2r_E21902-000Foodreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥420.6bn |
| jpcrp040300-q2r_E21902-000Foodreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥420.4bn |
| jpcrp040300-q2r_E21902-000Foodreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥278m |
| jpcrp040300-q2r_E21902-000Foodreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥29.3bn |
| jpcrp040300-q2r_E21902-000Pharmaceutica002reportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥97.2bn |
| jpcrp040300-q2r_E21902-000Pharmaceutica002reportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥97.2bn |
| jpcrp040300-q2r_E21902-000Pharmaceutica002reportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥13m |
| jpcrp040300-q2r_E21902-000Pharmaceutica002reportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥14.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥517.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥517.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥292m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥44.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 552
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E21902-000Pharmaceutica002ReportableSegmentsMember | 97167000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 517520000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 517520000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E21902-000FoodReportableSegmentsMember | 278000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E21902-000Pharmaceutica002ReportableSegmentsMember | 13000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 292000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -292000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E21902-000FoodReportableSegmentsMember | 420631000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E21902-000Pharmaceutica002ReportableSegmentsMember | 97181000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 517812000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -292000000 | JPY |
| Net sales | Prior1YTDDuration | 517520000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E21902-000FoodReportableSegmentsMember | 29329000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E21902-000Pharmaceutica002ReportableSegmentsMember | 14649000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 43979000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -786000000 | JPY |
| Operating income | Prior1YTDDuration | 43193000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E21902-000FoodReportableSegmentsMember | 445196000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E21902-000Pharmaceutica002ReportableSegmentsMember | 100850000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 546047000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 546047000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E21902-000FoodReportableSegmentsMember | 293000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E21902-000Pharmaceutica002ReportableSegmentsMember | 9000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 303000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -303000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E21902-000FoodReportableSegmentsMember | 445489000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E21902-000Pharmaceutica002ReportableSegmentsMember | 100860000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 546350000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -303000000 | JPY |
| Net sales | CurrentYTDDuration | 546047000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E21902-000FoodReportableSegmentsMember | 29684000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E21902-000Pharmaceutica002ReportableSegmentsMember | 15902000000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 45586000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -1142000000 | JPY |
| Operating income | CurrentYTDDuration | 44443000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2023-11-10 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第15期第２四半期（自 2023年７月１日 至 2023年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)明治ホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | Meiji Holdings Co.,Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役 社長 CEO 川村 和夫 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都中央区京橋二丁目４番16号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)03(3273)4001(代表) | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)経営管理部長 島田 勇人 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |